Lixte Biotechnology Holdings, Inc. - Current Ratio

The Current Ratio as of September 2026 (TTM) for Lixte Biotechnology Holdings, Inc. (LIXT) is 12.87

According to Lixte Biotechnology Holdings, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 12.87. This represents a change of 71.81% compared to the average of 7.49 of the last 4 quarters.

Lixte Biotechnology Holdings, Inc. (LIXT) Historical Current Ratio (quarterly & annually)

How has LIXT Current Ratio performed in the past?

The mean historical Current Ratio of Lixte Biotechnology Holdings, Inc. over the last ten years is 0.78. The current 12.87 Current Ratio has changed 165.51% with respect to the historical average. Over the past ten years (40 quarters), LIXT's Current Ratio was at its highest in in the June 2026 quarter at 12.87. The Current Ratio was at its lowest in in the September 2021 quarter at 0.

Lixte Biotechnology Holdings, Inc. (LIXT) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Lixte Biotechnology Holdings, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Lixte Biotechnology Holdings, Inc. (LIXT) Average Current Ratio

How has LIXT Current Ratio performed in the past?

The current Current Ratio of Lixte Biotechnology Holdings, Inc. (LIXT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Lixte Biotechnology Holdings, Inc. (LIXT) Current Ratio vs. Peers

How is LIXT’s Current Ratio compared to its peers?

Lixte Biotechnology Holdings, Inc.’s Current Ratio is greater than Kairos Pharma, Ltd. (11.98), greater than Lexaria Bioscience Corp. (10.60), greater than Allarity Therapeutics, Inc. (1.11), greater than Cingulate Inc. (3.50), greater than BriaCell Therapeutics Corp. (7.07), greater than Pulmatrix, Inc. (4.70), greater than Entero Therapeutics, Inc. (0.16), greater than Hoth Therapeutics, Inc. (6.20), greater than Clearside Biomedical, Inc. (2.98), greater than CASI Pharmaceuticals, Inc. (0.15),

Build a custom stock screener for Lixte Biotechnology Holdings, Inc. (LIXT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lixte Biotechnology Holdings, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Lixte Biotechnology Holdings, Inc. (LIXT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Lixte Biotechnology Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.